Meeting Report
Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
Presented by Cesar Rodriguez, MD, and Donna Catamero, ANP-BC, OCN®, CCRC
From Mount Sinai School of Medicine, New York, New York
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2023;14(3):252–256 |
https://doi.org/10.6004/jadpro.2023.14.3.14 |
© 2023 Harborside™
ABSTRACT
Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations that drive resistance and result in progressively shorter durations of remission to each subsequent therapy. At JADPRO Live 2022, presenters discussed the multifactorial process for choosing the right therapy for a particular patient and strategies to manage unique treatment complications associated with novel treatment modalities used for patients with relapsed/refractory multiple myeloma.
For access to the full length article, please
sign in.
